TARS
HealthcareTarsus Pharmaceuticals, Inc.
$79.75
$-1.02 (-1.26%)
Jan 5, 2026
Price History (1Y)
Analysis
Tarsus Pharmaceuticals, Inc. is a healthcare company operating in the biotechnology sector with a market capitalization of $3.39 billion and 323 employees. The company's revenue has experienced significant growth, reaching $366.10 million on a trailing twelve-month (TTM) basis. The company's financial health is characterized by negative profitability metrics, including a net income loss of $81.158 million on a TTM basis and an EBITDA loss of $85.609 million. The operating margin stands at -12.2%, while the profit margin is -22.2%. However, the company maintains a strong cash position with $401.84 million in cash reserves, supported by a current ratio of 4.29. The valuation context for Tarsus Pharmaceuticals reflects a forward price-to-earnings (P/E) ratio of 59.84 and a revenue growth rate of 146.7% year-over-year (YoY). The company's debt-to-equity ratio is 24.62, indicating a relatively high level of indebtedness.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is also developing TP-04 for the treatment of Ocular Rosacea; TP-05 for potential Lyme disease prophylaxis; and community malaria reduction. In addition, the company develops lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Visit website →Key Statistics
- Market Cap
- $3.39B
- P/E Ratio
- N/A
- 52-Week High
- $85.25
- 52-Week Low
- $38.51
- Avg Volume
- 555.46K
- Beta
- 0.60
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 323